What is the emergency management for a large fecalith (fecal impaction) in a 2-year-old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: April 28, 2025 • View editorial policy

From the Guidelines

Emergency management for a large fecalith in a 2-year-old requires prompt medical attention, with the primary goal of disimpaction, typically starting with oral polyethylene glycol (PEG 3350, such as MiraLAX) at a dose of 1-1.5 g/kg/day for 3-6 days, as recommended by the most recent guidelines 1. The management approach should prioritize the child's stability, with assessment of vital signs and hydration status. Key considerations include:

  • Ensuring adequate pain management with acetaminophen (15 mg/kg every 4-6 hours) or ibuprofen (10 mg/kg every 6-8 hours) 1
  • Using enemas, such as saline enemas (5-10 mL/kg) or mineral oil enemas (2-4 mL/kg), if oral therapy is ineffective or the situation is severe 1
  • Considering manual disimpaction under sedation in a hospital setting for very large or impacted fecaliths that don't respond to these measures 1
  • Implementing maintenance therapy with stool softeners, increased fluid intake, dietary fiber, and regular toileting habits to prevent recurrence, as emphasized in the guidelines 2, 1 Prompt intervention is crucial to prevent complications, including bowel obstruction, perforation, or significant pain and distress for the child. The most recent and highest quality study, published in 2016 1, provides the basis for these recommendations, prioritizing the child's morbidity, mortality, and quality of life as the primary outcomes.

From the Research

Emergency Management for Large Fecalith in a 2-Year-Old

  • The management of a large fecalith in a 2-year-old requires careful consideration of the potential complications, such as intestinal obstruction and rectal ischemia, as highlighted in a case report of a giant fecalith in an institutionalized paraplegic patient 3.
  • Polyethylene glycol (PEG) with or without electrolytes has been shown to be effective in the treatment of functional constipation and fecal impaction in pediatric patients, with a high safety and tolerability profile 4, 5.
  • A study evaluating the use of PEG in the treatment of severe constipation and fecal impaction in adults found that it was highly effective and well-tolerated, with an excellent response rate of 89.3% 6.
  • In pediatric patients, the presence of a fecalith has been associated with earlier and higher rates of appendiceal perforation, highlighting the importance of expedient treatment 7.
  • The choice between PEG with or without electrolytes should be based on the individual patient's needs, as both formulations have similar effectiveness and safety profiles, although PEG without electrolytes may produce more electrolyte abnormalities 5.

Related Questions

What is the appropriate workup and treatment for a 1-year-old patient presenting to the Emergency Room (ER) with constipation lasting 4 days?
What is the next step in managing an 8-year-old female with suspected anxiety-related abdominal pain episodes and constipation, who has leukopenia (low White Blood Cell Count), mild polycythemia (elevated Packed Cell Volume), and normal hemoglobin (HB) levels?
Can polyethylene glycol (Miralax) be taken with diverticulosis?
Is it safe to take Miralax (polyethylene glycol) while breastfeeding?
How is propylene glycol (PG) taken for the treatment of constipation?
What is the mechanism of action of Ivabradine (Ivabradine) in treating conditions such as tachycardia?
Which of the following cases requires screening for hematuria due to glomerular disease: a 60-year-old male with initial gross hematuria, an asymptomatic adult male with incidental dipstick-positive hematuria, a female of childbearing age with initial gross hematuria, or gross hematuria with flank pain?
Is cyproheptadine effective for treating Inflammatory Bowel Disease (IBD) or ulcerative colitis?
What are the BEAUTIFUL (MorBidity-mortality EvAlUation of the IF inhibitor ivabradine in patients with coronary disease and left ventriculAr dysfunction) and SHIFT (Systolic Heart failure treatment with the IF inhibitor ivabradine Trial) trials for ivabradine (ivabradine)?
What are the BEAUTIFUL (MorBidity-mortality EvAlUation of the IF inhibitor ivabradine in patients with coronary disease and left ventriculAr dysfunction) and SHIFT (Systolic Heart failure treatment with the IF inhibitor ivabradine Trial) trials for ivabradine (ivabradine)?
What is the treatment for angular cheilitis (cheilitis) caused by a fungal infection (mycosis)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.